(Q36314054)

13 August 2017

1 reference

title

Androgen deficiency in the etiology and treatment of erectile dysfunction (English)

1 reference

13 August 2017

1 reference

3

Jacob Rajfer

1 reference

13 August 2017

John L Gore

1

1 reference

13 August 2017

Ronald S Swerdloff

series ordinal

2

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Urologic Clinics of North America

13 August 2017

published in

1 reference

13 August 2017

volume

32

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

457-68, vi-vii

1 reference

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Response to Nonadrenergic, Noncholinergic Neurotransmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Nitric oxide: a physiologic mediator of penile erection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Restoration of normal adult penile erectile response in aged rats by long-term treatment with androgens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Role of androgens in erectile function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

The male menopause: does it exist?: for: some men need investigation and testosterone treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

The endocrinology of aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Circadian variation in serum free and non-SHBG-bound testosterone in normal men: measurements, and simulation using a mass action model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Testosterone and leptin in older African-American men: relationship to age, strength, function, and season

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Age, Disease, and Changing Sex Hormone Levels in Middle-Aged Men: Results of the Massachusetts Male Aging Study*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Circadian rhythm of testosterone and prolactin in the ageing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Loss of circadian rhythmicity in blood testosterone levels with aging in normal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Ageing of the hypothalamo-pituitary-testicular axis in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Endogenous sex hormone levels in older adult men with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Validation of a screening questionnaire for androgen deficiency in aging males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

An assessment of the clinical relevance of serum testosterone level determination in the evaluation of men with low sexual drive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Laboratory evaluations of erectile dysfunction: an evidence based approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Is routine endocrine testing of impotent men necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Endocrine dysfunction in impotence: incidence, significance and cost-effective screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Evaluation of assays available to measure free testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

A critical evaluation of simple methods for the estimation of free testosterone in serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Andropause: clinical implications of the decline in serum testosterone levels with aging in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgen therapy in the aging male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Treatment of androgen deficiency in the aging male

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Oral androgens in the treatment of hypogonadal impotent men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Methyltestosterone-induced cholestasis. The importance of disproportionately low serum alkaline phosphatase level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

7 January 2021

Transdermal testosterone

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgens: risks and benefits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Spouse-related drug side-effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

An analysis of testosterone implants for androgen replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Oral androstenedione administration and serum testosterone concentrations in young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Risks of testosterone-replacement therapy and recommendations for monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Prostate cancer after exogenous testosterone treatment for impotence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Androgens and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

The short-term effects of high-dose testosterone on sleep, breathing, and function in older men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Testosterone and regional fat distribution.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Testosterone influences spatial cognition in older men.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Sex steroids modify working memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Testosterone and cognition in elderly men: a single testosterone injection blocks the practice effect in verbal fluency, but has no effect on spatial or verbal memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

Replacing testosterone in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2005.08.002

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UCL.2005.08.002

1 reference

13 August 2017

1 reference